001065.KS
JW Pharmaceutical Corporation
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 22,650.00
+0.00%Year over year
Reported trailing growth
- Revenue
- +10.4%
- EBITDA
- +7.5%
- EBIT
- +24.6%
- EPS
- +98.2%
- Free cash flow
- +347.3%
- Operating cash flow
- +160.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.2%
- EBITDA
- +13.2%
- EBIT
- +11.8%
- Net income
- +24.6%
- EPS
- +26.0%
- Free cash flow
- +24.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026